

# ANUH PHARMA LTD.

CIN: L24230MH1960PLC011586


Regd. Office : 3-A, North Wing, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400018

Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com; Website: www.anuhpharma.com

## UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31<sup>ST</sup> DECEMBER, 2017

(Rs. in Lakhs)

| Sr. No.   | Particulars  | 3 months ended<br>31/12/2017 | 3 months ended<br>30/09/2017 | 3 months ended<br>31/12/2016 | 9 months ended<br>31/12/2017 | 9 months ended<br>31/12/2016 |
|---|--|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|   |  | Unaudited                    | Unaudited                    | Unaudited                    | Unaudited                    | Unaudited                    |
| I.  | Revenue from operations (Refer note. 4)  | 6,332.91                     | 5,585.52                     | 5,663.88                     | 17,413.83                    | 15,984.81                    |
| II.   | Other income (Refer note. 6)   | 156.87                       | 272.57                       | 122.40                       | 584.64                       | 523.80                       |
| III.  | <b>Total Revenue (I + II)</b>  | <b>6,489.78</b>              | <b>5,858.09</b>              | <b>5,786.28</b>              | <b>17,998.47</b>             | <b>16,508.61</b>             |
| IV.   | Expenses:  |                              |                              |                              |                              |                              |
|   | Cost of materials consumed   | 4,977.98                     | 4,364.43                     | 3,485.79                     | 13,214.60                    | 10,845.39                    |
|   | Purchases of Stock-in-Trade  | 9.97                         | -                            | 39.00                        | 9.97                         | 39.00                        |
|   | Changes in inventories of finished goods, work-in progress and Stock-in-Trade  | (116.81)                     | (85.37)                      | 297.80                       | (191.80)                     | 287.17                       |
|   | Employee benefits expense  | 217.52                       | 222.37                       | 146.89                       | 639.18                       | 485.29                       |
|   | Finance costs  | 0.29                         | 0.12                         | 0.35                         | 0.44                         | 1.43                         |
|   | Depreciation and amortization expense  | 44.37                        | 45.13                        | 51.49                        | 131.00                       | 144.49                       |
|   | Excise duty (Refer note.4)   | -                            | -                            | 340.61                       | 315.92                       | 840.37                       |
|   | Other expenses (Refer note.7)  | 687.78                       | 886.78                       | 839.02                       | 2,018.24                     | 1,888.56                     |
|   | <b>Total expenses (IV)</b>   | <b>5,821.10</b>              | <b>5,433.46</b>              | <b>5,200.95</b>              | <b>16,137.55</b>             | <b>14,531.70</b>             |
| V.  | <b>Profit / (Loss) before exceptional and items and tax (III - IV)</b>   | <b>668.68</b>                | <b>424.63</b>                | <b>585.33</b>                | <b>1,860.92</b>              | <b>1,976.91</b>              |
| VI.   | Exceptional items  | -                            | -                            | -                            | -                            | -                            |
| VII.  | <b>Profit / (Loss) before tax (V - VI)</b>   | <b>668.68</b>                | <b>424.63</b>                | <b>585.33</b>                | <b>1,860.92</b>              | <b>1,976.91</b>              |
| VIII.   | Tax expense:   |                              |                              |                              |                              |                              |
|   | (1) Current tax  | 177.00                       | 174.00                       | 150.00                       | 493.00                       | 500.00                       |
|   | (2) Deferred tax   | (1.71)                       | 43.92                        | (0.25)                       | 42.21                        | (0.75)                       |
|   |  | <b>175.29</b>                | <b>217.92</b>                | <b>149.75</b>                | <b>535.21</b>                | <b>499.25</b>                |
| IX.   | <b>Profit/(Loss) after Tax (VII-VIII)</b>  | <b>493.39</b>                | <b>206.71</b>                | <b>435.58</b>                | <b>1,325.71</b>              | <b>1,477.66</b>              |
| X.  | Other Comprehensive Income (net of Tax)  |                              |                              |                              |                              |                              |
|   | (i) Items that will not be reclassified to profit or loss  | 2.42                         | 2.00                         | (0.16)                       | 10.43                        | (0.48)                       |
|   | (ii) Items that will be reclassified to profit or loss   | -                            | -                            | -                            | -                            | -                            |
|   | <b>Total Other Comprehensive Income (net of Tax)</b>   | <b>2.42</b>                  | <b>2.00</b>                  | <b>(0.16)</b>                | <b>10.43</b>                 | <b>(0.48)</b>                |
| XI.   | <b>Total Comprehensive Income for the period (IX + X) (Comprising Profit / (Loss) and Other Comprehensive Income for the period)</b> | <b>495.81</b>                | <b>208.71</b>                | <b>435.42</b>                | <b>1,336.14</b>              | <b>1,477.18</b>              |
| XII.  | Earnings per equity share (for continuing operations and discontinued operations) (Non annualised) (In Rs.)                          |                              |                              |                              |                              |                              |
|   | (1) Basic  | 1.97                         | 0.83                         | 1.74                         | 5.29                         | 5.90                         |
|   | (2) Diluted  | 1.97                         | 0.83                         | 1.74                         | 5.29                         | 5.90                         |
| See accompanying notes to the financial results |  |                              |                              |                              |                              |                              |



1 The results of the quarter & nine months ended 31<sup>st</sup> December, 2017 were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 13<sup>th</sup> February, 2018. They have been subjected to limited review by the Statutory Auditor.

2 This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning 1<sup>st</sup> April, 2017, the Company has for the first time adopted Ind AS with a transition date of 1<sup>st</sup> April, 2016.

3 The format for unaudited quarterly results as prescribed in SEBI's Circular CIR/CFD/CMD/15/2015 dated 30<sup>th</sup> November, 2015 has been modified to comply with the requirements of SEBI's circular dated 5<sup>th</sup> July, 2016, Ind AS and Schedule III (Division II) to the Companies Act, 2013, which are applicable to companies that are required to comply with Ind AS.

4 Revenue from operations for the period upto 30<sup>th</sup> June, 2017 are inclusive of excise duty in accordance with requirements of Ind AS. Effective from 01<sup>st</sup> July, 2017 with implementation of Goods and Service Tax (GST), the revenue from operation for the quarter ended 30<sup>th</sup> September, 2017 and quarter ended 31<sup>st</sup> December, 2017 are exclusive of GST. Hence, the revenue from operations for the quarter and nine months ended on 31<sup>st</sup> December, 2017 are not comparable with the amounts reported in the corresponding previous periods.

5 The reconciliation of net profit reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind AS for the Quarter and Nine months ended 31<sup>st</sup> December, 2016 is given below:

| PARTICULARS   | (Rs. in Lakhs)   |   |
|---|--|---|
|   | For the quarter ended<br>31 <sup>st</sup> December, 2016 | For the nine months<br>ended<br>31 <sup>st</sup> December, 2016 |
| <b>Net Profit/(Loss) after Tax as per previous IGAAP</b>                      | <b>424.88</b>  | <b>1,301.01</b>   |
| Net Impact on Investments - Fair value option through P&L                     | 11.17  | 178.07  |
| Reclassification of net actuarial loss on employee defined benefit obligation | (0.72)   | (2.17)  |
| Impact of taxes in respect of the above adjustments                           | 0.25   | 0.75  |
| <b>Net Profit/(Loss) after Tax as per Ind AS</b>                              | <b>435.58</b>  | <b>1,477.66</b>   |
| <b>Other Comprehensive Income</b>   |  |   |
| Reclassification of net actuarial loss on employee defined benefit obligation | (0.25)   | (0.74)  |
| Impact of taxes in respect of the above adjustments                           | 0.09   | 0.26  |
| <b>Total Comprehensive Income for the period</b>                              | <b>435.42</b>  | <b>1,477.18</b>   |

6 Other Income includes mark to market gain on investment as follows:

| Particulars                   | Amount<br>(Rs. In lakhs) |
|-------------------------------|--------------------------|
| For 3 months ended 31/12/2017 | 87.22                    |
| For 3 months ended 31/12/2016 | 11.17                    |
| For 9 months ended 31/12/2016 | 178.07                   |

7 Other Expenses includes mark to market loss on investment as follows:

| Particulars                   | Amount<br>(Rs. In lakhs) |
|-------------------------------|--------------------------|
| For 3 months ended 30/09/2017 | 288.85                   |
| For 9 months ended 31/12/2017 | 136.21                   |

8 The Company has identified Bulk drug and Chemicals as its only primary reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no-separate segment information has been provided.

9 Previous period's figures have been regrouped and reclassified, wherever necessary, to correspond with those of the current period.

Place : Mumbai  
Dated : 13<sup>th</sup> February, 2018

For Anuh Pharma Limited

*Bipin N. Shah*  
Bipin N. Shah  
Managing Director  
(DIN: 00083244)



**REVIEW REPORT TO THE BOARD OF DIRECTORS OF**  
**ANUH PHARMA LIMITED**

We have reviewed the accompanying Statement of Unaudited Financial Results of **Anuh Pharma Limited** ("the Company") for the quarter and nine months ended 31st December, 2017 ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016. This Statement is the responsibility of the Company's Management and approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable Indian Accounting Standards and other recognised accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For JAYANTILAL THAKKAR & CO.**  
**CHARTERED ACCOUNTANTS**  
**(FIRM REG. NO. 104133W)**



**PLACE: Mumbai**  
**DATE: 13<sup>th</sup> February, 2018**

*V. A. Merchant*

**VIRAL A. MERCHANT**  
**PARTNER**  
**MEMBERSHIP NO. 116279**